1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5 GLOBAL ESOPHAGEAL CANCER MARKET, BY TYPE
5.1 ESOPHAGEAL SQUAMOUS-CELL CARCINOMA, ,
5.2 ESOPHAGEAL ADENOCARCINOMA
5.3 OTHERS
6 GLOBAL ESOPHAGEAL CANCER MARKET, BY PHASES
6.1 PHASE I
6.2 PHASES II
6.3 PHASES III
7 GLOBAL ESOPHAGEAL CANCER MARKET, BY TREATMENT
7.1 SURGERY
7.1.1 CHEMOTHERAPY AND RADIOTHERAPY
7.1.2 OTHER
8. GLOBAL ESOPHAGEAL CANCER MARKET, BY REGION
8.1 NORTH AMERICA
8.1.1 INTRODUCTION
8.2 EUROPE
8.2.1 INTRODUCTION
8.3 ASIA-PACIFIC
8.3.1 INTRODUCTION
8.4 MIDDLE EAST & AFRICA
8.4.1 INTRODUCTION
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 AMGEN
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 ELI LILLY AND COMPANY,
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 F. HOFFMANN-LA ROCHE
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 KEY DEVELOPMENT
10.4 BRISTOL-MYERS
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 SQUIBB COMPANY
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 BOEHRINGER INGELHEIM GMBH
10.6.1 OVERVIEW
10.6.2 PRODUCT OVERVIEW
10.6.3 FINANCIALS
10.6.4 KEY DEVELOPMENTS
10.7 BRISTOL-MYERS SQUIBB
10.7.1 OVERVIEW
10.7.2 PRODUCT OVERVIEW
10.7.3 FINANCIALS
10.7.4 KEY DEVELOPMENTS
10.8 GLAXOSMITHKLINE PLC.
10.8.1 OVERVIEW
10.8.2 PRODUCT OVERVIEW
10.8.3 FINANCIALS
10.8.4 KEY DEVELOPMENTS
10.9 NOVARTIS AG
10.9.1 OVERVIEW
10.9.2 PRODUCT OVERVIEW
10.9.3 FINANCIALS
10.9.4 KEY DEVELOPMENTS
10.10 JOHNSON & JOHNSON
10.10.1 OVERVIEW
10.10.2 PRODUCT OVERVIEW
10.10.3 FINANCIALS
10.10.4 KEY DEVELOPMENTS
10.11 GILEAD SCIENCES
10.11.1 OVERVIEW
10.11.2 PRODUCT OVERVIEW
10.11.3 FINANCIALS
10.11.4 KEY DEVELOPMENTS
10.12 MERCK & CO.
10.12.1 OVERVIEW
10.12.2 PRODUCT OVERVIEW
10.12.3 FINANCIALS
10.12.4 KEY DEVELOPMENTS
10.13 OTHERS
11 CONCLUSION
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
11.3 PREDICTION OF ESOPHAGEAL CANCER Solutions INDUSTRY
12 APPENDIX